Download MendeleyOptimization of Potent ATAD2 and CECR2 Bromodomain Inhibitors with an Atypical Binding Mode.
Lucas, S.C.C., Atkinson, S.J., Bamborough, P., Barnett, H., Chung, C.W., Gordon, L., Mitchell, D.J., Phillipou, A., Prinjha, R.K., Sheppard, R.J., Tomkinson, N.C.O., Watson, R.J., Demont, E.H.(2020) J Med Chem 63: 5212-5241
- PubMed: 32321240
- DOI: https://doi.org/10.1021/acs.jmedchem.0c00021
- Primary Citation of Related Structures:
6YB4 - PubMed Abstract:
Most bromodomain inhibitors mimic the interactions of the natural acetylated lysine (KAc) histone substrate through key interactions with conserved asparagine and tyrosine residues within the binding pocket. Herein we report the optimization of a series of phenyl sulfonamides that exhibit a novel mode of binding to non-bromodomain and extra terminal domain (non-BET) bromodomains through displacement of a normally conserved network of four water molecules. Starting from an initial hit molecule, we report its divergent optimization toward the ATPase family AAA domain containing 2 (ATAD2) and cat eye syndrome chromosome region, candidate 2 (CECR2) domains. This work concludes with the identification of ( R )-55 (GSK232), a highly selective, cellularly penetrant CECR2 inhibitor with excellent physicochemical properties.
Organizational Affiliation:
WestCHEM, Department of Pure and Applied Chemistry, University of Strathclyde, Thomas Graham Building, 295 Cathedral Street, Glasgow G1 1XL, United Kingdom.
